Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal A+C conjugate vaccine
- Development stage
- Unknown
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal A+C conjugate vaccine is a combination vaccine designed to protect against invasive disease caused by Neisseria meningitidis serogroups A and C. It consists of purified capsular polysaccharides from serogroups A and C, each covalently linked (conjugated) to a carrier protein, typically diphtheria or tetanus toxoid. The conjugation enhances immunogenicity by inducing a T-cell dependent immune response, resulting in stronger and longer-lasting immunity compared to plain polysaccharide vaccines. This type of vaccine is primarily used for the prevention of epidemic outbreaks in regions where serogroups A and/or C are prevalent, such as parts of Africa's "meningitis belt" or during specific outbreak responses elsewhere. The primary mechanism is the induction of protective antibodies that neutralize Neisseria meningitidis bacteria expressing these capsular antigens.
- Other names
- MenA+C conjugate vaccineMeningococcal group A and C conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal A+C conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal A+C conjugate vaccine.